Startseite Medizin Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats

  • Shvetank Bhatt EMAIL logo , Radhakrishnan Mahesh , Ankur Jindal und Thangaraj Devadoss
Veröffentlicht/Copyright: 23. September 2016

Abstract

Background:

Several preclinical studies have shown that serotonergic 5-HT3 receptor antagonists play an important role in the management of neuropsychiatric disorders, such as depression and anxiety. In the present study the compound “6n” (N-n-propyl-3-ethoxyquinoxaline-2-carboxamide), a novel 5-HT3 receptor antagonist with an optimal log P (2.52) and pA2 (7.6) value was screened for its neuro-pharmacological potential in chronic rodent models of depression and anxiety named traumatic brain injury (TBI).

Methods:

In this model, a 1 cm midline scalp incision was made, and the muscles were retracted to expose the skull. A stainless steel disc (10 mm in diameter and 3 mm in depth) was placed centrally between the lambda and bregma regions. The injury was induced using the impact acceleration model of TBI. Specifically, a 400 g metal weight was dropped from a height of 1 m guided by a straight pipe, onto the metal disc placed over the rat’s skull.

Results:

The behavioral anomalies of the TBI rats were attenuated by the chronic treatment of compound 6n (1 and 2 mg/kg, p.o.; 14 days) as observed by the modified open field test (ambulation, rearing, and fecal pellet), sucrose consumption test (% sucrose consumption), elevated plus maze [% open arm entries [OAE] and % time spent in open arm (TSOA)], and marble burying test (numbers). In addition, 6n also increased the levels of neurotransmitters (norepinephrine and serotonin) and brain derived neurotrophic factor (BDNF) in TBI rats.

Conclusions:

The result suggests that compound 6n exhibited antidepressant- and anxiolytic-like effects in rodent models of depression and anxiety.


Corresponding author: Dr. Shvetank Bhatt, Department of Pharmacology, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka 560054, India, Phone: +919414822323

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Available at: http://www.adaa.org/understanding-anxiety/depression. Accessed 14 Feb 2016.Suche in Google Scholar

2. Robert MA, Hirschfeld MD. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. J Clin Psychiatry 2001;3:244–54.10.4088/PCC.v03n0609Suche in Google Scholar

3. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35:47–56.10.1016/j.tins.2011.11.004Suche in Google Scholar PubMed PubMed Central

4. Available at: http://www.ncbi.nlm.nih.gov/books/NBK63740/. Accessed 27 Feb 2016.Suche in Google Scholar

5. Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252–65.10.1139/jpn.0427Suche in Google Scholar

6. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns. Curr Pharm Des 2004;10:2463–75.10.2174/1381612043383872Suche in Google Scholar PubMed PubMed Central

7. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012;4:93–101.10.2147/DHPS.S28804Suche in Google Scholar PubMed PubMed Central

8. Hamet P, Tremblay J. Genetics and genomics of depression. Metabolism 2005;54:10–15.10.1016/j.metabol.2005.01.006Suche in Google Scholar PubMed

9. Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Pandey DK. Anti-depressant potential of 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm 2012;4:235–44.10.4103/0975-1483.104367Suche in Google Scholar PubMed PubMed Central

10. Bhatt S, Mahesh R, Devadoss T, Jindal AK. Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): an approach using rodent behavioral antidepressant tests. Indian J Pharmacol 2013;45:348–53.10.4103/0253-7613.115014Suche in Google Scholar PubMed PubMed Central

11. Betry C, Etievant A, Oosterhof C, Ebert B, Sanchez C, Haddjeri N. Role of 5-HT3 Receptors in the Antidepressant Response. Pharmaceuticals 2011;4:603–29.10.3390/ph4040603Suche in Google Scholar

12. Bhatt S, Mahesh R, Jindal A, Devadoss T. Anti-depressant-like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist. Indian J Exp Biol 2013;51: 435–443.Suche in Google Scholar

13. Gupta D, Mahesh R, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P. Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression. Acta Pharmacol Sin 2014;35:1493–1503.10.1038/aps.2014.89Suche in Google Scholar PubMed PubMed Central

14. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor indepression: a probable neuronal target. J Psychopharmacol 2010;24:455–69.10.1177/0269881109348161Suche in Google Scholar PubMed

15. Vitalis S, Ansorge MS, Dayer AG. Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes. Front Cell Neurosci 2013;7:93.10.3389/fncel.2013.00093Suche in Google Scholar PubMed PubMed Central

16. Sziray N, Leveleki C, Levay G, Harsing LG, Mikics E. Mechanism underlying the long term behavioural effects of traumatic experience in rats: the role of serotonin/noradrenaline balance and NMDA receptors. Brain Res Bull 2007;71:376–85.10.1016/j.brainresbull.2006.10.006Suche in Google Scholar

17. Foda MA, Marmarou A. A new model of diffuse brain injury in rats; Part II: morphological characterization. J Neurosurg 1994;80:301–13.10.3171/jns.1994.80.2.0301Suche in Google Scholar

18. Heath DL, Vink R. Optimization of magnesium therapy following severe diffuse axonal brain injury in rats. J Pharm Exp Ther 1999;288:1311–16.10.1016/S0022-3565(24)38087-5Suche in Google Scholar

19. Mahesh R, Pandey DK, Katiyar S, Kukade G, Viyogi S, Rudra A. Effect of Anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats. Indian J Exp Biol 2010;48:466–73.Suche in Google Scholar

20. Pandey DK, Yadav SK, Mahesh R, Ramamoorthy R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety. Behav Brain Res 2009;205:436–442.10.1016/j.bbr.2009.07.027Suche in Google Scholar

21. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997;74:299–316.10.1016/S0163-7258(97)00004-1Suche in Google Scholar

22. Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima, M. Neurobehavioural alterations in mice with a targeted deletion of the tumor necrosis factor-α gene: implications for emotional behaviour. J Neuroimmunol 2000;111:131–38.10.1016/S0165-5728(00)00375-1Suche in Google Scholar

23. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525–34.10.1016/S0149-7634(05)80194-0Suche in Google Scholar

24. Broekkamp CL, Rijk HW, Joly-gelo D, Lloyd KG. Major tranquilizer can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim induced grooming in mice. Eur J Pharmacol 1986;126:223–29.10.1016/0014-2999(86)90051-8Suche in Google Scholar

25. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. I. The disposition of [3H] nor-epinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J Neurochem 1966;13:655–669.10.1111/j.1471-4159.1966.tb09873.xSuche in Google Scholar PubMed

26. Jorge R, Robinson RG. Mood disorders following traumatic brain injury. Neurorehabilitation 2002;17:311–24.10.3233/NRE-2002-17405Suche in Google Scholar

27. Kersel DA, Marsh NV, Havill JH, Sleigh JW. Psychosocial functioning during the year following severe traumatic brain injury. Brain Inj 2001;15:683–96.10.1080/02699050010013662Suche in Google Scholar PubMed

28. Ramamoorthy R, Radhakrishnan M, Borah M. Anti-depressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008;19:29–40.10.1097/FBP.0b013e3282f3cfd4Suche in Google Scholar

29. Kulkarni SK. Open Field Test: its status in psychopharmacology. Indian J Pharmacol 1977;9:241–46.Suche in Google Scholar

30. Grahame K, Robyn L, Tate DL. Preventing suicide after traumatic brain injury: implications for general practice. Med J Aust 2007;187:229–32.10.5694/j.1326-5377.2007.tb01206.xSuche in Google Scholar

31. Berkowitz L. Aggression: its causes, consequences, and control. McGraw-Hill Series in Social Psychology. New York, NY: Mcgraw-Hill Book Company, 1993.Suche in Google Scholar

32. Hogg S. A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 1996;54:21–30.10.1016/0091-3057(95)02126-4Suche in Google Scholar

33. Wang D, Noda Y, Tsunekawa H, Masayuk Y, Zhoub SK, Nabeshima T. Behavioural and neuro-chemical features of olfactory bulbectomized rats resembling depression with co-morbid anxiety. Behav Brain Res 2007;178:262–273.10.1016/j.bbr.2007.01.003Suche in Google Scholar PubMed

34. Available at: http://www.apa.org/helpcenter/symptoms-of-depression.aspx.Suche in Google Scholar

35. Jones NC, Cardamone L, Williams JP, Salzberg MR, Myers D, O’Brien TJ. Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats. J Neurotrauma 2008;2:1367–74.10.1089/neu.2008.0641Suche in Google Scholar PubMed

36. Koponen S, Taiminen T, Portin R. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 2002;159:1315–21.10.1176/appi.ajp.159.8.1315Suche in Google Scholar PubMed

37. Jorge R, Robinson RG, Moser D. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004;61:42–50.10.1001/archpsyc.61.1.42Suche in Google Scholar PubMed

38. Michael AJ, Brandum AD. Obsessive-compulsive disorder and head trauma: a rare association. J Anxiety Disord 1988;4:353–60.10.1016/0887-6185(88)90030-8Suche in Google Scholar

39. Ichimaru, Y, Egawa T, Sawa A. 5-HT 1A receptor subtype mediates the effect of fluvoxamine, a selective serotonin re-uptake inhibitor on marble burying behaviour in mice. Jpn J Pharmacol 1995;68:65–73.10.1254/jjp.68.65Suche in Google Scholar PubMed

40. Levine J, Cole DP, Chengappa KN, Gershon S. Anxiety disorders and major depression, together or apart. Depress Anxiety 2001;14:94–104.10.1002/da.1051Suche in Google Scholar PubMed

41. Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation 2012;9:236–47.10.1186/1742-2094-9-236Suche in Google Scholar PubMed PubMed Central

Received: 2016-4-14
Accepted: 2016-7-19
Published Online: 2016-9-23
Published in Print: 2017-3-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Antidepressant and anxiolytic-like, sedation and hypnosis
  4. Behavior and Neuroprotection
  5. Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats
  6. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice
  7. Effect of Salacia reticulata W. and Clitoria ternatea L. on the cognitive and behavioral changes in the streptozotocin-induced young diabetic rats
  8. In vivo sedative and hypnotic activities of methanol extract from the leaves of Jacquemontia paniculata (Burm.f.) Hallier f. in Swiss Albino mice
  9. Reproduction
  10. Bonny light crude oil-induced alteration in levels of testicular stress proteins is accompanied by apoptosis in rats after treatment withdrawal
  11. Cardiovascular-Pulmonary Interactions
  12. Meteorological parameters and pollutants on asthma exacerbation in Bangalore, India – an ecological retrospective time-series study
  13. Oxidative Stress
  14. Antioxidant and acetylcholinesterase inhibitory activities of leaf extract and fractions of Albizia adianthifolia (Schumach) W.F. Wright
  15. Oxidative stress, histopathological and electron microscopic alterations induced by dimethylnitrosamine in renal male mice and the protective effect of α-lipoic acid
  16. Effects of altered thyroid states on oxidative stress parameters in rats
  17. Metabolism
  18. The effects of smoking and nicotine ingestion on exercise heat tolerance
  19. Inflammation
  20. Investigation of antinociceptive activity of methanolic extract of Persicaria orientalis leaves in rodents
  21. Infection
  22. Antiplasmodial activity of the ethanolic root bark extract of Icacina senegalensis in mice infected by Plasmodium berghei
  23. Phytotherapy
  24. Evaluation of cytotoxic, analgesic, antidiarrheal and phytochemical properties of Hygrophila spinosa (T. Anders) whole plant
Heruntergeladen am 6.2.2026 von https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2016-0057/pdf?lang=de
Button zum nach oben scrollen